慢性髓性白血病的预后:基线因素,动态风险评估和新见解
Miriam Iezza1, Sofia Cortesi1, Emanuela Ottaviani2
1Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Università di Bologna, 40138 Bologna, Italy.
氨酸激酶抑制剂改善了慢性髓性白血病 (CML) 的结果,但识别高风险患者对于更好的治疗和潜在的无治疗缓解 (TFR) 至关重要. 本综述涵盖了改善CML管理的预后因素.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 氨酸激酶抑制剂 (TKIs) 彻底改变了慢性髓性白血病 (CML) 的治疗方法,显著改善了患者的预后,并实现了无治疗缓解 (TFR) 的目标.
- 然而,有一小部分患者经历治疗失败,进展到晚期 (AP,BP),预后不佳.
研究的目的:
- 审查关于CML预后因素的当前知识.
- 探索它们在完善风险分类和指导治疗决策以改善疾病管理中的作用.
主要方法:
- 关于慢性髓性白血病预后因素的当前文献的综述.
- 临床,血液学,细胞遗传学和基因组参数的分析.
- 在诊断和TKI治疗期间评估风险分层策略.
主要成果:
- 基线风险评估涉及临床,血液学参数和额外的染色体异常 (ACA).
- 在TKI治疗期间必须重新评估风险.
- 新兴的见解突出了基因组因素在诊断和治疗期间的作用.
结论:
- 准确识别高风险的CML患者是有效管理的优先事项.
- 整合各种预后因素,包括基因组见解,可以提高风险分类和个性化治疗策略.
- 改进的风险分层有望为CML患者提供更好的结果和优化治疗决策.
更多相关视频
06:33Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
相关概念视频
Cancer Survival Analysis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Differentiation of Common Myeloid Progenitor Cells
